Zacks: Analysts Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $330,000.00

Equities research analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGNGet Rating) to report $330,000.00 in sales for the current quarter, Zacks reports. Two analysts have provided estimates for VistaGen Therapeutics’ earnings, with the lowest sales estimate coming in at $300,000.00 and the highest estimate coming in at $360,000.00. VistaGen Therapeutics posted sales of $440,000.00 in the same quarter last year, which suggests a negative year over year growth rate of 25%. The business is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that VistaGen Therapeutics will report full year sales of $1.42 million for the current year, with estimates ranging from $1.40 million to $1.43 million. For the next year, analysts anticipate that the business will report sales of $1.27 million, with estimates ranging from $1.10 million to $1.43 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow VistaGen Therapeutics.

VistaGen Therapeutics (NASDAQ:VTGNGet Rating) last released its quarterly earnings results on Thursday, February 10th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.02. VistaGen Therapeutics had a negative return on equity of 44.10% and a negative net margin of 2,465.94%. During the same period in the previous year, the business earned ($0.07) earnings per share.

Separately, Zacks Investment Research raised VistaGen Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a report on Wednesday, February 16th.

Institutional investors have recently added to or reduced their stakes in the stock. CWM LLC purchased a new stake in VistaGen Therapeutics during the fourth quarter valued at about $26,000. Eagle Asset Management Inc. purchased a new stake in VistaGen Therapeutics during the fourth quarter valued at about $30,000. Mackenzie Financial Corp purchased a new stake in VistaGen Therapeutics during the third quarter valued at about $31,000. Zacks Investment Management purchased a new stake in VistaGen Therapeutics during the third quarter valued at about $33,000. Finally, E Fund Management Co. Ltd. purchased a new stake in VistaGen Therapeutics during the third quarter valued at about $38,000. Hedge funds and other institutional investors own 65.78% of the company’s stock.

Shares of NASDAQ VTGN traded up $0.06 during trading on Tuesday, reaching $1.39. The company had a trading volume of 2,598,589 shares, compared to its average volume of 1,527,840. VistaGen Therapeutics has a twelve month low of $1.06 and a twelve month high of $3.55. The stock has a market capitalization of $287.07 million, a PE ratio of -3.86 and a beta of 1.00. The stock has a 50-day moving average price of $1.32 and a two-hundred day moving average price of $1.81.

About VistaGen Therapeutics (Get Rating)

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.

Featured Stories

Get a free copy of the Zacks research report on VistaGen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VistaGen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.